Y828F/Y858F mutants and pharmacological inhibition of Src (using PP2) significantly inhibit the CD133-p85 interaction and Akt activation in glioma cells and then its self-renewal and tumor-initiating capacity [61]. The gene discussed is PROM1; the disease is central nervous system cancer.